Xia CQ - Search Results

1

Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.

Xia CQ, Yang JJ, Gan LS. Xia CQ, et al. Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):595-611. doi: 10.1517/17425255.1.4.595. Expert Opin Drug Metab Toxicol. 2005. PMID: 16863427 Review.

2

Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells.

Xia CQ, Liu N, Yang D, Miwa G, Gan LS. Xia CQ, et al. Drug Metab Dispos. 2005 May;33(5):637-43. doi: 10.1124/dmd.104.003442. Epub 2005 Feb 16. Drug Metab Dispos. 2005. PMID: 15716365

3

Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.

Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS. Lu C, et al. Among authors: xia cq. Drug Metab Dispos. 2006 Apr;34(4):702-8. doi: 10.1124/dmd.105.008060. Epub 2006 Jan 27. Drug Metab Dispos. 2006. PMID: 16443666

4

Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays.

Xia CQ, Xiao G, Liu N, Pimprale S, Fox L, Patten CJ, Crespi CL, Miwa G, Gan LS. Xia CQ, et al. Mol Pharm. 2006 Jan-Feb;3(1):78-86. doi: 10.1021/mp050034j. Mol Pharm. 2006. PMID: 16686372

5

Interactions of cyclosporin a with breast cancer resistance protein.

Xia CQ, Liu N, Miwa GT, Gan LS. Xia CQ, et al. Drug Metab Dispos. 2007 Apr;35(4):576-82. doi: 10.1124/dmd.106.011866. Epub 2007 Jan 12. Drug Metab Dispos. 2007. PMID: 17220244

6

Evaluation of drug-transporter interactions using in vitro and in vivo models.

Xia CQ, Milton MN, Gan LS. Xia CQ, et al. Curr Drug Metab. 2007 May;8(4):341-63. doi: 10.2174/138920007780655423. Curr Drug Metab. 2007. PMID: 17504223 Review.

7

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.

Williamson MJ, Silva MD, Terkelsen J, Robertson R, Yu L, Xia C, Hatsis P, Bannerman B, Babcock T, Cao Y, Kupperman E. Williamson MJ, et al. Mol Cancer Ther. 2009 Dec;8(12):3234-43. doi: 10.1158/1535-7163.MCT-09-0239. Mol Cancer Ther. 2009. PMID: 19934276

8

Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-drug interactions.

Liao M, Raczynski AR, Chen M, Chuang BC, Zhu Q, Shipman R, Morrison J, Lee D, Lee FW, Balani SK, Xia CQ. Liao M, et al. Among authors: xia cq. Drug Metab Dispos. 2010 Sep;38(9):1612-22. doi: 10.1124/dmd.110.032995. Epub 2010 Jun 1. Drug Metab Dispos. 2010. PMID: 20516252

9

P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.

Yang JJ, Milton MN, Yu S, Liao M, Liu N, Wu JT, Gan L, Balani SK, Lee FW, Prakash S, Xia CQ. Yang JJ, et al. Among authors: xia cq. Drug Metab Lett. 2010 Dec;4(4):201-12. doi: 10.2174/187231210792928279. Drug Metab Lett. 2010. PMID: 20670210

10

Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions.

Lu C, Liao M, Cohen L, Xia CQ. Lu C, et al. Among authors: xia cq. Curr Drug Discov Technol. 2010 Sep;7(3):199-222. doi: 10.2174/157016310793180549. Curr Drug Discov Technol. 2010. PMID: 20843292 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results